NCT05695911

Brief Summary

This randomized controlled trial (n=25 enrolled, n=15 expected to complete) will 1) determine the feasibility of a 40-week limb-load biofeedback training intervention, 2) determine if there is an intervention signal of efficacy, and 3) identify functional movement priorities for people with transfemoral osseointegrated (OI) prostheses. A limb-load biofeedback training group (EXP (n=10)) will be compared to a standard of care attention-control group without limb-load biofeedback training (CTL (n=5)). Outcomes will be assessed at standard of care pre-habilitation end (Week 5), standard of care rehabilitation end (Week 24), and one year after OI Stage 2 surgery (Week 64).

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
9mo left

Started Jan 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress82%
Jan 2023Jan 2027

First Submitted

Initial submission to the registry

January 5, 2023

Completed
20 days until next milestone

First Posted

Study publicly available on registry

January 25, 2023

Completed
5 days until next milestone

Study Start

First participant enrolled

January 30, 2023

Completed
4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2027

Last Updated

April 27, 2026

Status Verified

April 1, 2026

Enrollment Period

4 years

First QC Date

January 5, 2023

Last Update Submit

April 24, 2026

Conditions

Keywords

amputationosseointegrationrehabilitationbiofeedback

Outcome Measures

Primary Outcomes (5)

  • Intervention Feasibility

    Intervention feasibility is measured by retention rate, the percentage of people that complete the study. A score can range between 0 and 100 percent with 100 percent meaning all randomized participants completed the study.

    Week 64

  • Intervention Participant Acceptability

    Acceptability of an intervention is the perception among stakeholders (e.g., patients and clinicians) that the intervention is agreeable or satisfactory. To measure participant acceptability, the investigators will use the Acceptability of Intervention Measure, a 30 four-item survey of stakeholder perception of intervention acceptability that asks participants to provide their approval as well as intervention appeal, likability, and agreeability. The scores range from 1 (completely disagree) to 5 (completely agree). The investigators expect the Acceptability of Intervention Measure score (average of the four items on a 1-5 scale) for the EXP group to be at least 4 (agree).

    Week 64

  • Intervention Fidelity

    This will be evaluated based on whether EXP group interventionists deliver the intervention as planned and quantified in three ways: adherence, delivery quality, and patient engagement. The investigators will use the overall results of these three fidelity components to create a total score. Fidelity scores are reported as a percentage from 0 to 100 with 100 representing full fidelity. The investigators will consider \>85% fidelity (average across all three components) to intervention delivery as a positive result.

    Week 64

  • Change in Cumulative Loading

    Free-living physical activity will be objectively monitored over a 10-day period using an activPAL micro accelerometer-based sensor (PAL Technologies, Glasgow, UK). Interlimb cumulative loading will be measured as a product of daily step count and ground reaction force impulse. Cumulative loading = (Daily Steps/2)\*ground reaction force impulse.

    Week 5, Week 64

  • Change in Multi-Domain Biomechanics during Tasks of Increasing Biomechanical Demand

    Bilateral hip movement patterns (joint angles), muscle forces, and joint reaction forces will be calculated during functional tasks of increasing biomechanical demand (walking, sitting, stepping, turning) using a combination of motion capture and subject-specific musculoskeletal models. Whole-body motion capture will be collected from 70 reflective markers (Fs=120 Hz) (Vicon, Centennial, CO) with ground reaction forces simultaneously collected from six embedded force platforms (Fs=2,160 Hz) (Bertec, Columbus, OH). A subject-specific musculoskeletal model will be created using OpenSim software.

    Week 5, Week 64

Secondary Outcomes (7)

  • Change in World Health Organization-Disability Assessment Schedule 2.0

    Week 5, Week 24 and Week 64

  • Change in Activities Specific Balance Confidence Scale

    Week 5, Week 24 and Week 64

  • Change in Prosthetic Limb Users Survey of Mobility

    Week 5, Week 24 and Week 64

  • Change in Patient Specific Function Scale

    Week 5, Week 24 and Week 64

  • Change in Self Selected Gait Speed

    Week 5 and Week 64

  • +2 more secondary outcomes

Study Arms (2)

Limb Load Biofeedback Training Intervention

EXPERIMENTAL

The limb-load biofeedback training focuses on altering habitual movement patterns to promote proper prosthetic limb loading with an emphasis on between-limb loading symmetry. Participants randomized to the EXP group will receive 12 biofeedback training sessions (1 in-person, 11 telehealth) tapered over 40 weeks.

Behavioral: Limb Load Biofeedback Training Intervention

Attention Control Intervention

PLACEBO COMPARATOR

The CTL group intervention will include the same standard of care rehabilitation sessions as the EXP group and receive the same computer tablets for telehealth sessions as the EXP group. The CTL group will also have attention control educational sessions at the same frequency, timing, and duration as the EXP group limb-load biofeedback sessions (12 total sessions) with the first session being an in-person session at the Week 24. There will be no biofeedback training intervention in the CTL group. As such, there will be no behavioral intervention or wearable sensors provided to the CTL group. The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group.

Other: Attention Control

Interventions

Loadsol data will be used to inform the EXP telehealth sessions, as the interventionist guides the participant to self-monitor their movement, problem solve movement patterns that promote asymmetrical limb loading, and create weekly action plans for improving limb load symmetry. Weekly goals will be made in the context of functional task progression over the 40-week intervention.

Limb Load Biofeedback Training Intervention

The 12 sessions of EXP group limb-load biofeedback training sessions will be replaced by education-only session in the CTL group. The CTL group sessions will include a review of the standard of care home-exercises, a summary of healthcare visits and falls, and interventionist-delivered education on safety topics (e.g., fall prevention, wound care, assistive device use, home safety).

Attention Control Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Transfemoral unilateral amputation due to traumatic, congenital or cancer related causes
  • ≥ 18 years old
  • History of severe socket-related skin or residual limb problems
  • Schedule for OI prosthesis implantation surgery

You may not qualify if:

  • Vascular amputation etiology
  • Substance abuse
  • Unstable heart condition
  • Acute systemic infection
  • Cognitive impairment (Montreal Cognitive Assessment \[MoCA\] score \<24)
  • Active cancer treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CU Physical Therapy

Aurora, Colorado, 80045, United States

Location

Study Officials

  • Cory Christiansen, PT PHD

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Participants will be randomized by ratio of 1:2 in the CTL to EXP group.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2023

First Posted

January 25, 2023

Study Start

January 30, 2023

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

January 31, 2027

Last Updated

April 27, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will share

The investigators will publish the trial results data on the ClinicalTrials.gov website, on which the clinical trial will be registered. Sharing of data will include the potential of sharing raw data generated from all clinical assessments under a data-sharing agreement.

Shared Documents
ICF
Time Frame
The investigators will publish the trial results within one year of testing the final participant.
Access Criteria
User registration will be required to access/download any data and will require agreement to conditions of use in accordance with CDMRP Policy on Sharing Data and Research Resources.

Locations